Immuron Limited (IMRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMRN Stock Summary
- For IMRN, its debt to operating expenses ratio is greater than that reported by only 0.51% of US equities we're observing.
- With a year-over-year growth in debt of -100%, IMMURON LTD's debt growth rate surpasses just 0% of about US stocks.
- Revenue growth over the past 12 months for IMMURON LTD comes in at -70.87%, a number that bests just 2.37% of the US stocks we're tracking.
- Stocks that are quantitatively similar to IMRN, based on their financial statements, market capitalization, and price volatility, are UG, ORGO, CETX, DDI, and MGIC.
- Visit IMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.immuron.com.au.
IMRN Stock Price Chart Interactive Chart >
IMRN Price/Volume Stats
| Current price | $2.02 | 52-week high | $4.40 |
| Prev. close | $2.00 | 52-week low | $1.69 |
| Day low | $2.02 | Volume | 1,400 |
| Day high | $2.10 | Avg. volume | 268,216 |
| 50-day MA | $2.02 | Dividend yield | N/A |
| 200-day MA | $2.58 | Market Cap | 11.50M |
Immuron Limited (IMRN) Company Bio
Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.
Latest IMRN News From Around the Web
Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.
Immuron completes strategic investment in leading gut health biotech Ateria HealthHighlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health, including products that |
Immuron CEO, Steven Lydeamore to present at AusBioInvestMELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore. A copy |
Immuron Announces Strategic Investment In UK-Based Gut Health CompanyImmuron Limited (NASDAQ: IMRN) signed a strategic investment and option agreement with Ateria Health Limited for an upfront cash investment of £1.48 million. The company has also announced a strategic investment of approximately £1.5 million (A$2.6 million) to acquire an initial 17.5% of Ateria Health. Potential adjustment to share percentage for Immuron dependent on Ateria's performance during its CY2023. Ateria Health Ltd is a U.K.-based health and wellness company that has developed a novel i |
Immuron strategic investment in leading gut health biotech Ateria HealthHighlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health, including products that strengthen the gut microbiome. Ateria has developed and recently launched a ground-breaki |
Immuron Executes Travelan Clinical Trial Agreement with US-based PharmaronHighlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy volunteers in the USAClinical Trial to examine a dosing regimen for Travelan more suited for use by the US militaryInfectious diarrhea is the most common illness reported by travelers MELBOURNE, Australia, Oct. 04 |
IMRN Price Returns
| 1-mo | 11.25% |
| 3-mo | N/A |
| 6-mo | -30.82% |
| 1-year | -33.66% |
| 3-year | -48.86% |
| 5-year | -58.52% |
| YTD | -19.20% |
| 2021 | -60.75% |
| 2020 | 75.48% |
| 2019 | N/A |
| 2018 | 0.00% |
| 2017 | N/A |
Continue Researching IMRN
Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...